trial · primary record
IL-12 GEMys
Relapsed Solid Tumor Malignancies
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 95 |
| Primary completion | 2029-01-15 |
| Primary endpoint | Part A (Escalation): Determine the recommended phase 2 dose (RP2D) of IL-12 |
| Registry ID | NCT07672483 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:27:37.422Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07672483
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.